HC Wainwright & Co. Downgrades Sanara MedTech to Neutral, Lowers Price Target to $35
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsDowngradesPrice Target
HC Wainwright & Co. analyst Yi Chen downgrades Sanara MedTech (NASDAQ:SMTI) from Buy to Neutral and lowers the price target from $36 to $35.
HC Wainwright & Co. analyst Yi Chen downgrades Sanara MedTech (NASDAQ:SMTI) from Buy to Neutral and lowers the price target from $36 to $35.